Laboratory Medicine Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Endothelial NO Synthase Polymorphic Gene in Coronary Artery Dilation Disease
Conditions: Coronary Artery Ectasia Interventions: Diagnostic Test: The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs Sponsors: Cairo University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials

a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection （PROFOUND）
Conditions: Cancer Sponsors: Shanghai Weihe Medical Laboratory Co., Ltd.; Peking University People ' s Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials

A Phase 1, Placebo-controlled, Single-Ascending-Dose, Study of BIOPIN 6 in Healthy Adults
Conditions: Opioid Use Disorder Interventions: Combination Product: BIOPIN-6 Active Implant with Naltrexone; Device: BIOPIN-6 Placebo Implant Sponsors: Drug Delivery Company, LLC DBA Akyso Pharmaceuticals; National Institute on Drug Abuse (NIDA); Laboratory Corporation of America; Cognitive Research Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials

Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy
The objective of this study is to evaluate the safety, efficacy, and appropriate dosing of a 4-month regimen of QBS in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary TB in comparison with the 6-month standard treatment (i.e., rifampicin, isoniazid, ethambutol, and pyrazinamide).MethodsThis phase 2b/c, open-label, randomized, parallel group, dose-finding trial will enroll approximately 120 participants (including no more than 15% with human immunodeficiency virus [HIV] coinfection) aged ≥ 18 to ≤ 65 years at screening with newly diagnosed pulmonary drug-sensitive TB from ~8 si...
Source: Trials - January 19, 2024 Category: Research Source Type: clinical trials

Anemia in Systemic Lupus Erythematosus Specially Refractory Type
Conditions: Refractory Anemia in Systemic Lupus Erythematosis Interventions: Combination Product: Laboratory investigtions Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials

The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis —study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study
This study aims to evaluate the efficacy and safety of MTX in maintaining remission in patients with GCA who have previously been treated with GC and at least 6 months with TCZ. We hypothesize that MTX can maintain remission in GCA patients, who have achieved stable remission after treatment with GC and TCZ, and prevent the occurrence of relapses. The study design is a monocentric, randomized, double-blind, placebo-controlled, parallel-group phase II tria l randomizing 40 GCA patients 1:1 into a MTX or placebo arm. Patients will receive 17.5 mg MTX/matching placebo weekly by subcutaneous injection for 12 months, with t...
Source: Trials - January 15, 2024 Category: Research Source Type: clinical trials

Atalante Exoskeleton in the Rehabilitation of Patients With Amyotrophic Lateral Sclerosis
Conditions: ALS - Amyotrophic Lateral Sclerosis Interventions: Device: Atalante exoskeleton Sponsors: Institut de Recherche sur la Moelle épinière et l ' Enc éphale; Association pour la Recherche sur la Sclérose Latérale Amyotrophique et autres Maladies du Motoneurone; Groupe Hospitalier Pitie-Salpetriere; Institut de Myologie, France; Station Debout; Laboratory of Biomedical Imaging Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2024 Category: Research Source Type: clinical trials

Early Warning and Classification Model for Acute Non-traumatic Chest Pain
Conditions: Chest Pain Interventions: Combination Product: Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization Sponsors: Xiao-nan He Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials

Human Laboratory Study of the Effects of Nicotine Product Claims on Appeal, Perceptions, and Use Behavior
Conditions: Behavior, Risk Interventions: Behavioral: 3x3 between-subjects experimental exposure Sponsors: Ohio State University Comprehensive Cancer Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
Conditions: SARS-CoV-2 Infection; Influenza A; Influenza B Interventions: Diagnostic Test: Aptitude Medical Systems Metrix COVID/Flu Test Sponsors: Aptitude Medical Systems; Biomedical Advanced Research and Development Authority Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials

Efficacy and Safety of MOX/ALB Co-administration in SAC
Conditions: Trichuriasis; Ascariasis; Hookworm Infections Interventions: Drug: Moxidectin 2 mg Oral Tablet; Drug: Albendazole 400 mg Oral Tablet; Drug: Placebo MOX; Drug: Placebo ALB Sponsors: Jennifer Keiser; Public Health Laboratory Ivo de Carneri Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2024 Category: Research Source Type: clinical trials

Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
Conditions: Trichuriasis; Ascariasis; Hookworm Infections Interventions: Drug: Ivermectin 1.5 mg ODT; Drug: Ivermectin 3 mg Oral Tablet; Drug: Albendazole 400 mg Oral Tablet; Drug: Placebo IVM ODT Sponsors: Jennifer Keiser; Public Health Laboratory Ivo de Carneri Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 28, 2023 Category: Research Source Type: clinical trials

Greater-Bay-Area Healthy Aging Brain Study (GHABS)
Conditions: Alzheimer ' s Disease Interventions: Diagnostic Test: Fluids biomarker and neuroimaging of AD diagnosis Sponsors: Shenzhen Bay Laboratory; National Natural Science Foundation of China; Guangdong Basic and Applied Basic Science Foundation; Shenzhen Science and Technology Innovation Commission Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2023 Category: Research Source Type: clinical trials

Efficacy and safety of voriconazole in the treatment of invasive pulmonary aspergillosis in patients with liver failure: study protocol for a randomized controlled clinical trial
This study is a non-double-blind randomized controlled trial. The 96 eligible acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis will be randomly assigned to receive either the optimized voriconazole regimen or the recommended voriconazole regimen for patients with mild to moderate liver cirrhosis (Child –Pugh A and B), at a 1:1 ratio, with an 8-week follow-up period. The antifungal efficacy of voriconazole will be the primary outcome measure. Plasma voriconazole trough concentration, the laboratory examination (CRP, PCT, ESR, etc.), chest CT, adverse events, and mortality at week 4...
Source: Trials - December 17, 2023 Category: Research Source Type: clinical trials

Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression
Conditions: Treatment Resistant Depression Interventions: Device: Active iTBS-DLPFC; Device: Sham iTBS-DLPFC Sponsors: Changping Laboratory; Xianyue Hospital, Xiamen; Hebei Mental Health Center, Baoding; HuiLongGuan Hospital, Beijing; Wuhan Mental Health Center, Wuhan; Zhumadian Second People ' s Hospital, Zhumadian Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 12, 2023 Category: Research Source Type: clinical trials